Implementation to Motivate Physician Response to Opioid Dependence in HIV Settings
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Baystate Medical Center
- Enrollment
- 294
- Locations
- 4
- Primary Endpoint
- Change in naloxone prescribing behavior
Study Overview
Brief Summary
The U.S. is in the midst of an epidemic of opioid overdose deaths. The common use of opioids among persons living with HIV, along with their common use of benzodiazepines, has resulted in high rates of opioid overdose among this population. This study will test the implementation of evidence-based training, mentoring, technical support, and academic detailing to encourage HIV physicians to adopt evidence-based interventions to reduce overdose risk and treat opioid addiction.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Health Services Research
- Masking
- None
Eligibility Criteria
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Clinicians and staff of HIV practice sites that:
- •Receive Ryan White Funding;
- •Treat adults with HIV;
- •Have 3 or more prescribing clinicians;
- •Have an electronic medical record (EMR) with an electronic medication list.
Exclusion Criteria
- •Sites located in states with fewer than 500 Persons Living With HIV (PLWH) will be excluded
Outcomes
Primary Outcomes
Change in naloxone prescribing behavior
Time Frame: baseline to 6 months
Number of clinicians that prescribe naloxone. This information will be collected from electronic medical record (EMR) data.
Secondary Outcomes
- Change in perception about pharmacotherapy for opioid use disorder; 6-month(baseline to 6 months)
- Change in prescribing motivation; 6 months(baseline to 6 months)
- Change in buprenorphine prescribing behavior(baseline to 12 months)
- Change in prescriber training(baseline to 12 months)
- Change in perception about pharmacotherapy for opioid use disorder; 12-month(baseline to 12 months)
- Change in prescribing motivation; 12 months(baseline to 12 months)
Investigators
Peter Friedmann
Chief Research Officer and Endowed Chair for Clinical Research
Baystate Medical Center